Axon Enterprise, Inc $AXON Holdings Trimmed by PKO Investment Management Joint Stock Co

PKO Investment Management Joint Stock Co reduced its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 22.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,400 shares of the biotechnology company’s stock after selling 1,300 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Axon Enterprise were worth $2,499,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Baillie Gifford & Co. boosted its position in shares of Axon Enterprise by 1,198.7% during the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after purchasing an additional 1,516,099 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Axon Enterprise by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after purchasing an additional 376,904 shares in the last quarter. Jennison Associates LLC lifted its stake in Axon Enterprise by 53.8% during the third quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after purchasing an additional 330,213 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Axon Enterprise by 23.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 838,289 shares of the biotechnology company’s stock valued at $476,089,000 after purchasing an additional 156,647 shares during the last quarter. Finally, Artisan Partners Limited Partnership boosted its holdings in Axon Enterprise by 2,541.0% during the third quarter. Artisan Partners Limited Partnership now owns 96,053 shares of the biotechnology company’s stock worth $68,931,000 after buying an additional 99,988 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Price Performance

AXON opened at $402.31 on Friday. The firm has a market capitalization of $32.41 billion, a P/E ratio of 264.68, a PEG ratio of 8.59 and a beta of 1.44. The stock has a fifty day moving average of $454.05 and a 200-day moving average of $534.17. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. Axon Enterprise, Inc has a 12-month low of $339.01 and a 12-month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.55. The firm had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.Axon Enterprise’s quarterly revenue was up 38.5% on a year-over-year basis. During the same period in the previous year, the firm earned $2.08 earnings per share. Equities analysts forecast that Axon Enterprise, Inc will post 1.41 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Jennifer H. Mak sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $573.45, for a total transaction of $860,175.00. Following the completion of the sale, the chief accounting officer directly owned 12,240 shares in the company, valued at approximately $7,019,028. This trade represents a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Erika Nardini sold 198 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total transaction of $100,302.84. Following the completion of the transaction, the director owned 1,946 shares in the company, valued at approximately $985,804.68. This represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 13,855 shares of company stock valued at $7,109,828 over the last ninety days. Insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

AXON has been the topic of several research reports. Robert W. Baird set a $800.00 price target on Axon Enterprise in a report on Wednesday, February 25th. Craig Hallum reissued a “buy” rating and set a $820.00 price objective on shares of Axon Enterprise in a research note on Wednesday, February 25th. The Goldman Sachs Group decreased their target price on Axon Enterprise from $720.00 to $625.00 and set a “buy” rating on the stock in a report on Wednesday, April 8th. Citigroup reaffirmed a “buy” rating on shares of Axon Enterprise in a report on Wednesday, February 25th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Axon Enterprise in a research report on Wednesday, April 8th. Sixteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus target price of $749.63.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.